Despina Kontos

Columbia University Irving Medical Center — United States

Medicine · Health Sciences

40h-index5.5kcitations320works1.72yr avg

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Radiomics and Machine Learning in Medical Imaging(156), AI in cancer detection(131), Digital Radiography and Breast Imaging(101), Medical Imaging Techniques and Applications(60), MRI in cancer diagnosis(57)

Publications320 total

Sex‐specific patterns of a machine learning‐derived Alzheimer's brain atrophy imaging signature in participants without diagnosed cognitive impairment: A multi‐cohort study

Alzheimer s & Dementia·2025Open Access

Association between Participant Characteristics and Breast Parenchymal Texture Variation among Postmenopausal Women

Cancer Epidemiology Biomarkers & Prevention·2025Open Access

Figure 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025Open Access

Data from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025Open Access

Table S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025Open Access

Table 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025Open Access

Table S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025Open Access

Table S5 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025Open Access

Figure S1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025Open Access

Table 3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025Open Access

Table 4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025Open Access

Figure S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025Open Access

Figure S2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025Open Access

Table 2 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025Open Access

Table S4 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025Open Access

Table S7 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025Open Access

Table S3 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025Open Access

Table S6 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025Open Access

Figure 1 from Phase I/II Study of AXL-Specific Antibody–Drug Conjugate Enapotamab Vedotin in Patients with Advanced Solid Tumors

2025Open Access

Novel 4D radiomics applied to dynamic FES PET images to improve prediction of breast cancer response to ER-targeted therapy

European Journal of Nuclear Medicine and Molecular Imaging·2025Open Access

page 1 of 16Next →

Frequent Co-authors

Emily F. Conant(25), Aimilia Gastounioti(13), Lauren Pantalone(8), Mark Rosen(7), Mitchell D. Schnall(6), Eric A. Cohen(6), Christos Davatzikos(6), Susan P. Weinstein(6), Brad M. Keller(5), Anne Marie McCarthy(5), Elizabeth S. McDonald(5), Shandong Wu(5), Andrew D. A. Maidment(5), Constance D. Lehman(4), Ahmed Ashraf(4), Dania Daye(4), Carolyn Mies(4), Rhea Chitalia(4), Jinbo Chen(4), Susan M. Domchek(4)